BACKGROUND: Results from salvage therapy in adult patients with acute lymphocytic leukemia (ALL) are wide-ranging and depend on several disease and patient characteristics. The objectives of this study were to define the prognosis for adult patients with ALL after first salvage through multivariate analyses of patient and disease characteristics. METHODS: Adults with ALL who had primary resistance to frontline therapy or who had a disease recurrence after a first complete response (CR) duration <1 year were analyzed. Multivariate analyses for subsequent CR and survival were conducted. RESULTS: Seventy-five of 245 patients (31%) achieved CR. The median CR duration was 5 months, the median survival was 4.7 months. In multivariate analysis, independent poor prognostic factors for not achieving CR were age >55 years, bone marrow blasts ≥20%, and platelet count <75 × 10(9) /L. Variables that were associated independently with shorter survival were age >55 years, bone marrow blasts ≥20%, platelet count <75 × 10(9) /L, albumin level <3 g/L, and lactic dehydrogenase level ≥1000 IU/L. Patients who had ≥3 of the 5 adverse factors (45%) had a median survival of 2 to 3 months and CR rates of 8% to 15%. Achieving CR was associated independently with improved survival in a landmark multivariate analysis (P < .0001; hazard ratio, 0.40; 95% confidence interval, 0.03-0.72). CONCLUSIONS: The current analyses identified a subset of adults patients ALL in first salvage for whom standard therapies were associated with an extremely poor outcome. The results also confirmed the importance of achieving CR to attain improved survival.
BACKGROUND: Results from salvage therapy in adult patients with acute lymphocytic leukemia (ALL) are wide-ranging and depend on several disease and patient characteristics. The objectives of this study were to define the prognosis for adult patients with ALL after first salvage through multivariate analyses of patient and disease characteristics. METHODS: Adults with ALL who had primary resistance to frontline therapy or who had a disease recurrence after a first complete response (CR) duration <1 year were analyzed. Multivariate analyses for subsequent CR and survival were conducted. RESULTS: Seventy-five of 245 patients (31%) achieved CR. The median CR duration was 5 months, the median survival was 4.7 months. In multivariate analysis, independent poor prognostic factors for not achieving CR were age >55 years, bone marrow blasts ≥20%, and platelet count <75 × 10(9) /L. Variables that were associated independently with shorter survival were age >55 years, bone marrow blasts ≥20%, platelet count <75 × 10(9) /L, albumin level <3 g/L, and lactic dehydrogenase level ≥1000 IU/L. Patients who had ≥3 of the 5 adverse factors (45%) had a median survival of 2 to 3 months and CR rates of 8% to 15%. Achieving CR was associated independently with improved survival in a landmark multivariate analysis (P < .0001; hazard ratio, 0.40; 95% confidence interval, 0.03-0.72). CONCLUSIONS: The current analyses identified a subset of adults patients ALL in first salvage for whom standard therapies were associated with an extremely poor outcome. The results also confirmed the importance of achieving CR to attain improved survival.
Authors: N Gökbuget; D Hoelzer; R Arnold; A Böhme; C R Bartram; M Freund; A Ganser; M Kneba; W Langer; T Lipp; W D Ludwig; G Maschmeyer; H Rieder; E Thiel; A Weiss; D Messerer Journal: Hematol Oncol Clin North Am Date: 2000-12 Impact factor: 3.722
Authors: A Thiebaut; J P Vernant; L Degos; F R Huguet; J Reiffers; C Sebban; E Lepage; X Thomas; D Fière Journal: Hematol Oncol Clin North Am Date: 2000-12 Impact factor: 3.722
Authors: D A Thomas; H Kantarjian; T L Smith; C Koller; J Cortes; S O'Brien; F J Giles; J Gajewski; S Pierce; M J Keating Journal: Cancer Date: 1999-10-01 Impact factor: 6.860
Authors: Hagop Kantarjian; Deborah Thomas; Susan O'Brien; Jorge Cortes; Francis Giles; Sima Jeha; Carlos E Bueso-Ramos; Sherry Pierce; Jianqin Shan; Charles Koller; Miloslav Beran; Michael Keating; Emil J Freireich Journal: Cancer Date: 2004-12-15 Impact factor: 6.860
Authors: Oliver G Ottmann; Brian J Druker; Charles L Sawyers; John M Goldman; Jose Reiffers; Richard T Silver; Sante Tura; Thomas Fischer; Michael W Deininger; Charles A Schiffer; Michele Baccarani; Alois Gratwohl; Andreas Hochhaus; Dieter Hoelzer; Sofia Fernandes-Reese; Insa Gathmann; Renaud Capdeville; Stephen G O'Brien Journal: Blood Date: 2002-09-15 Impact factor: 22.113
Authors: J B Nachman; H N Sather; M G Sensel; M E Trigg; J M Cherlow; J N Lukens; L Wolff; F M Uckun; P S Gaynon Journal: N Engl J Med Date: 1998-06-04 Impact factor: 91.245
Authors: E Tavernier; J-M Boiron; F Huguet; K Bradstock; N Vey; T Kovacsovics; A Delannoy; N Fegueux; P Fenaux; A Stamatoullas; O Tournilhac; A Buzyn; O Reman; C Charrin; C Boucheix; J Gabert; V Lhéritier; J-P Vernant; H Dombret; X Thomas Journal: Leukemia Date: 2007-07-05 Impact factor: 11.528
Authors: Daniel J DeAngelo; Daohai Yu; Jeffrey L Johnson; Steven E Coutre; Richard M Stone; Alison T Stopeck; Jon P Gockerman; Beverly S Mitchell; Frederick R Appelbaum; Richard A Larson Journal: Blood Date: 2007-03-07 Impact factor: 22.113
Authors: Anthony S Stein; Richard A Larson; Andre C Schuh; William Stevenson; Ewa Lech-Maranda; Qui Tran; Zachary Zimmerman; William Kormany; Max S Topp Journal: Blood Adv Date: 2018-07-10
Authors: Hagop Kantarjian; Anthony Stein; Nicola Gökbuget; Adele K Fielding; Andre C Schuh; Josep-Maria Ribera; Andrew Wei; Hervé Dombret; Robin Foà; Renato Bassan; Önder Arslan; Miguel A Sanz; Julie Bergeron; Fatih Demirkan; Ewa Lech-Maranda; Alessandro Rambaldi; Xavier Thomas; Heinz-August Horst; Monika Brüggemann; Wolfram Klapper; Brent L Wood; Alex Fleishman; Dirk Nagorsen; Christopher Holland; Zachary Zimmerman; Max S Topp Journal: N Engl J Med Date: 2017-03-02 Impact factor: 91.245
Authors: Gerhard Zugmaier; Nicola Gökbuget; Matthias Klinger; Andreas Viardot; Matthias Stelljes; Svenja Neumann; Heinz-A Horst; Reinhard Marks; Christoph Faul; Helmut Diedrich; Albrecht Reichle; Monika Brüggemann; Chris Holland; Margit Schmidt; Hermann Einsele; Ralf C Bargou; Max S Topp Journal: Blood Date: 2015-10-19 Impact factor: 22.113
Authors: Elias Jabbour; Nicholas J Short; Jeffrey L Jorgensen; Musa Yilmaz; Farhad Ravandi; Sa A Wang; Deborah A Thomas; Joseph Khoury; Richard E Champlin; Issa Khouri; Partow Kebriaei; Susan M O'Brien; Guillermo Garcia-Manero; Jorge E Cortes; Koji Sasaki; Courtney D Dinardo; Tapan M Kadia; Nitin Jain; Marina Konopleva; Rebecca Garris; Hagop M Kantarjian Journal: Cancer Date: 2016-09-07 Impact factor: 6.860
Authors: Nicola Gökbuget; Hervè Dombret; Jose-Maria Ribera; Adele K Fielding; Anjali Advani; Renato Bassan; Victoria Chia; Michael Doubek; Sebastian Giebel; Dieter Hoelzer; Norbert Ifrah; Aaron Katz; Michael Kelsh; Giovanni Martinelli; Mireia Morgades; Susan O'Brien; Jacob M Rowe; Julia Stieglmaier; Martha Wadleigh; Hagop Kantarjian Journal: Haematologica Date: 2016-09-01 Impact factor: 9.941